Sugi Predict

Sugi Predict / Compounds / SCHEMBL132240

SCHEMBL132240

SCHEMBL132240

CN(C(=O)OC(C)(C)C)C1CCC(=O)CC1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.41
▸ DDB1 Q16531 1/20 0.37
▸ CRBN Q96SW2 1/20 0.37
▸ ASGR1 P07306 1/20 0.37
▸ MT-CO2 P00403 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35
▸ RELA Q04206 1/20 0.35
▸ KDM4D Q6B0I6 1/20 0.34
▸ BUB1 O43683 1/20 0.34
▸ SPR P35270 6/20 0.34
▸ PDE10A Q9Y233 1/20 0.33
▸ KAT6A Q92794 1/20 0.32
▸ KAT8 Q9H7Z6 1/20 0.32
▸ USP30 Q70CQ3 1/20 0.32
▸ AAK1 Q2M2I8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24137969 0.94 HSD11B1 (0.38) HSD11B1DDB1CRBNASGR1MT-CO2
SCHEMBL25512753 0.92 HSD11B1 (0.40) HSD11B1DDB1CRBNASGR1MT-CO2
SCHEMBL31344262 0.92 HSD11B1 (0.40) HSD11B1DDB1CRBNASGR1MT-CO2
SCHEMBL5370355 0.92 HSD11B1 (0.40) HSD11B1DDB1CRBNASGR1MT-CO2
SCHEMBL190837 0.85 HSD11B1 (0.47) HSD11B1DDB1CRBNASGR1NFKB1
SCHEMBL14239667 0.85 HSD11B1 (0.40) HSD11B1DDB1CRBNASGR1NFKB1
SCHEMBL24969074 0.84 NFKB1 (0.41) HSD11B1DDB1CRBNMT-CO2NFKB1
SCHEMBL21274075 0.84 HSD11B1 (0.41) HSD11B1DDB1CRBNASGR1MT-CO2
SCHEMBL228179 0.83 HSD11B1 (0.46) HSD11B1ASGR1KDM4DSPRPDE10A
SCHEMBL1053454 0.82 HSD11B1 (0.39) HSD11B1DDB1CRBNASGR1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
US-12539295-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-03 — — US disclosed
US-12528785-B2 MDM2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-01-20 — — US disclosed
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-18 — — US disclosed
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-04 — — US disclosed
US-20250333417-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-30 — — US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 — — US disclosed
US-20250320205-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
US-20250320206-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
US-20050176766-A1 2,3-Oxidosqualene-lanosterol cyclase inhibitors ACKERMANN JEAN (CH) 2005-08-11 — — US disclosed
US-20050124649-A1 Deazapurines and uses thereof EISAI CO., LTD (JP) 2005-06-09 — — US disclosed
US-6858651-B2 2,3-oxidosqualene-lanosterol cyclase inhibitors HOFFMANN-LA ROCHE INC. (US) 2005-02-22 — — US disclosed
EP-1474425-A1 DEAZAPURINES AND USES THEREOF Eisai Co. Ltd. (JP) 2004-11-10 — — EP disclosed
US-20040186127-A1 Novel deazapurines and uses thereof EISAI CO., LTD. (JP) 2004-09-23 — — US disclosed
WO-2004063336-A2 USES OF DEAZAPURINES FOR THE TREATMENT OF REPERFUSION INJURIES, OSTEOPOROSIS AND/OR BONE METASTASIS EISAI CO. LTD. (JP) 2004-07-29 — — WO disclosed
WO-2003057696-A1 DEAZAPURINES AND USES THEREOF EISAI CO. LTD. (JP) 2003-07-17 — — WO disclosed
EP-1311475-A1 NOVEL AMINOCYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-05-21 — — EP disclosed
US-20020045777-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors F.HOFFMANN-LA ROCHE AG (CH) 2002-04-18 — — US disclosed
WO-2002014267-A1 NOVEL AMINOCYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 HSD11B1 2160/4885DDB1 511/4885CRBN 39/4885
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 HSD11B1 2337/4885DDB1 244/4885CRBN 1/4885
US-20050124649-A1 Deazapurines and uses thereof TPMT, CD38, CD2 HSD11B1 3331/4885DDB1 380/4885CRBN 1242/4885
US-12539295-B2 IRAK degraders and uses thereof IRAK2, IRAK4, IRAK3 HSD11B1 924/4885DDB1 2951/4885CRBN 70/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 HSD11B1 2310/4885DDB1 3966/4885CRBN 1627/4885
US-12528785-B2 MDM2 degraders and uses thereof MDM2, ADRM1, RBX1 HSD11B1 2734/4885DDB1 243/4885CRBN 18/4885
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 HSD11B1 2337/4885DDB1 244/4885CRBN 1/4885
US-20250320205-A1 STAT6 DEGRADERS STAT6, STAT1, STAT5B HSD11B1 2388/4885DDB1 3708/4885CRBN 1751/4885
US-20050176766-A1 2,3-Oxidosqualene-lanosterol cyclase inhibitors CYP51A1, LSS, CYP46A1 HSD11B1 14/4885DDB1 1841/4885CRBN 4236/4885
US-20250333417-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885DDB1 1267/4885CRBN 187/4885
US-20020045777-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors CYP51A1, LSS, CYP46A1 HSD11B1 14/4885DDB1 1841/4885CRBN 4236/4885
US-20250320206-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 HSD11B1 2310/4885DDB1 3966/4885CRBN 1627/4885
US-20040186127-A1 Novel deazapurines and uses thereof TPMT, ENTPD5, MTAP HSD11B1 1334/4885DDB1 150/4885CRBN 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.